Form 4: Rigel Pharmaceuticals Director Kamil Ali-Jackson Receives Equity Awards

Rigel Pharmaceuticals Inc. Director Kamil Ali-Jackson was granted 2,500 Restricted Stock Units and 3,000 stock options, aligning her interests with shareholders.

Summary

• Kamil Ali-Jackson, a Director at Rigel Pharmaceuticals Inc. (RIGL), reported changes in her beneficial ownership of company securities.
• On May 23, 2025, Ms. Ali-Jackson was granted 2,500 shares of Common Stock through a Restricted Stock Unit (RSU) award, with a transaction price of $0.
• These RSUs are set to fully vest on the date prior to the Company's next Annual Meeting, contingent on her continuous service on the Board of Directors.
• Additionally, on May 23, 2025, she was granted 3,000 stock options with an exercise price of $18.95 per share and a transaction price of $0.
• These stock options will vest monthly over one year from the grant date, also subject to her continuous service on the Board.
• Following these transactions, Ms. Ali-Jackson beneficially owns 9,375 shares of Common Stock and 3,000 stock options.
• The reported beneficial ownership of Common Stock (9,375 shares) has been adjusted to reflect a one-for-ten reverse stock split that became effective on June 27, 2024.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects routine compensation and alignment of director interests with shareholders, which is generally viewed favorably. There are no negative implications or unexpected events reported.

Positives

• The granting of Restricted Stock Units and stock options to a director aligns management's interests with those of shareholders, as the value of these awards is tied to the company's stock performance.
• The awards are part of a standard compensation structure for directors, indicating ongoing commitment and incentivization for long-term value creation.

Future Outlook

The vesting schedules for both the Restricted Stock Units and stock options are contingent on the director's continuous service on the Board, indicating an expectation of ongoing commitment and contribution to the company's governance and strategic direction.

Industry Context

Equity awards such as Restricted Stock Units and stock options are a common component of executive and director compensation packages in the biotechnology and pharmaceutical industries. They are designed to attract and retain talent, and to align the interests of key personnel with the long-term performance of the company and its shareholders.

Related Party Transactions

• The grants of Restricted Stock Units and stock options to Kamil Ali-Jackson, a director, constitute related party transactions as they involve compensation from the company to a member of its Board of Directors.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivization and retention of key personnel.

Next Steps

• The Restricted Stock Units are expected to fully vest on the date prior to the Company's next Annual Meeting, subject to continuous service.
• The stock options will vest monthly over one year from the date of grant, subject to continuous service.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Awards, Director Compensation, Beneficial Ownership, Reverse Stock Split